{"id":"https://openalex.org/W3213110313","doi":"https://doi.org/10.1182/blood-2021-150012","title":"Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium","display_name":"Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3213110313","doi":"https://doi.org/10.1182/blood-2021-150012","mag":"3213110313"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-150012","doi":"https://doi.org/10.1182/blood-2021-150012","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-150012","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058153938","display_name":"Kitsada Wudhikarn","orcid":"https://orcid.org/0000-0001-9528-8681","observed_orcids":["https://orcid.org/0000-0001-9528-8681"]},"institutions":[{"id":"https://openalex.org/I158708052","display_name":"Chulalongkorn University","ror":"https://ror.org/028wp3y58","country_code":"TH","type":"education","lineage":["https://openalex.org/I158708052"]}],"countries":["TH"],"is_corresponding":false,"raw_author_name":"Kitsada Wudhikarn","raw_affiliation_strings":["Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand","institution_ids":["https://openalex.org/I158708052"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089876625","display_name":"Ana Alarc\u00f3n Tom\u00e1s","orcid":"https://orcid.org/0000-0002-6290-1061","observed_orcids":["https://orcid.org/0000-0002-6290-1061"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ana Alarcon Tomas","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002908932","display_name":"Jamie Brower","orcid":"https://orcid.org/0000-0003-1614-8934","observed_orcids":["https://orcid.org/0000-0003-1614-8934"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamie Brower","raw_affiliation_strings":["Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067489954","display_name":"Veronika Bachanov\u00e1","orcid":"https://orcid.org/0000-0002-9325-432X","observed_orcids":["https://orcid.org/0000-0002-9325-432X"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Veronika Bachanova","raw_affiliation_strings":["Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082092102","display_name":"Richard Thomas Maziarz","orcid":"https://orcid.org/0000-0002-8184-7099","observed_orcids":["https://orcid.org/0000-0002-8184-7099"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard T. Maziarz","raw_affiliation_strings":["Knight Cancer Institute, Oregon Health and Science University, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052064208","display_name":"Joseph P. McGuirk","orcid":"https://orcid.org/0000-0002-0539-4796","observed_orcids":["https://orcid.org/0000-0002-0539-4796"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph P. McGuirk","raw_affiliation_strings":["Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037878906","display_name":"Loretta J. Nastoupil","orcid":"https://orcid.org/0000-0001-6071-8610","observed_orcids":["https://orcid.org/0000-0001-6071-8610"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Loretta Nastoupil","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047973111","display_name":"David L. Porter","orcid":"https://orcid.org/0000-0001-6333-9536","observed_orcids":["https://orcid.org/0000-0001-6333-9536"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David L. Porter","raw_affiliation_strings":["Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004821244","display_name":"Peter A. Riedell","orcid":"https://orcid.org/0000-0003-2719-0580","observed_orcids":["https://orcid.org/0000-0003-2719-0580"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter A. Riedell","raw_affiliation_strings":["Department of Medicine, The University of Chicago Medicine, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, The University of Chicago Medicine, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082333371","display_name":"Miguel\u2010Angel Perales","orcid":"https://orcid.org/0000-0002-5910-4571","observed_orcids":["https://orcid.org/0000-0002-5910-4571"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miguel-Angel Perales","raw_affiliation_strings":["Department of Medicine, Adult Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Adult Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"2843","last_page":"2843"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9580000042915344},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.953000009059906},{"id":"https://openalex.org/keywords/no-evidence-of-disease","display_name":"no evidence of disease","score":0.7889999747276306},{"id":"https://openalex.org/keywords/axicabtagene-ciloleucel","display_name":"axicabtagene ciloleucel","score":0.9459999799728394},{"id":"https://openalex.org/keywords/tisagenlecleucel","display_name":"tisagenlecleucel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.7419999837875366},{"id":"https://openalex.org/keywords/car-t-cell-persistence","display_name":"CAR T cell persistence","score":0.5740000009536743},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.8759999871253967},{"id":"https://openalex.org/keywords/immune-effector-cell-associated-neurotoxicity-syndrome","display_name":"immune effector cell-associated neurotoxicity syndrome","score":0.7599999904632568},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5109999775886536}],"concepts":[{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.8736288547515869},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.7762463092803955},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6798352003097534},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.524837076663971},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.517029345035553},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.514018177986145},{"id":"https://openalex.org/C10882517","wikidata":"https://www.wikidata.org/wiki/Q15268054","display_name":"Cell therapy","level":3,"score":0.4513031244277954},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.43655237555503845},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4112318754196167},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39688146114349365},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.34636104106903076},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.20025721192359924},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1674206256866455},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.13308918476104736},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-150012","doi":"https://doi.org/10.1182/blood-2021-150012","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-150012","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5600000023841858,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2917403768","https://openalex.org/W4381594543","https://openalex.org/W2952260713","https://openalex.org/W3142239825","https://openalex.org/W2969241243","https://openalex.org/W3204328954","https://openalex.org/W3199232787","https://openalex.org/W2977459329","https://openalex.org/W4281961745","https://openalex.org/W4231177780"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"CD19":[2,118,246,595],"chimeric":[3],"antigen":[4],"receptor":[5],"(CAR)":[6],"T":[7,46,79,120,126,181,188,195,248,266,315,341,360,379,400,414,429,491,597,609,639,659,674],"cells":[8,80,415,675],"provide":[9],"high":[10,325,682],"response":[11,192],"rates":[12],"and":[13,42,57,75,90,103,155,175,199,204,210,220,257,299,330,409,419,425,471,481,508,529,540,548,558,565,617,635,662,767,778,792,965,981],"durable":[14],"disease":[15,30,169,262,547,589,631],"remission":[16,283],"for":[17,40,679,963],"many":[18],"patients":[19,108,140,164,242,352,366,411,442,464,483,497,502,526,534,542,613,646,680],"with":[20,48,54,109,141,165,243,407,450,583,603,681],"relapsed/refractory":[21],"(R/R)":[22],"diffuse":[23],"large":[24],"B":[25,327],"cell":[26,121,127,182,189,196,213,249,267,316,328,342,361,380,430,492,598,640,660],"lymphoma":[27,329],"(DLBCL).":[28],"Pre-treatment":[29],"burden":[31,51,89,632],"has":[32],"been":[33],"identified":[34],"as":[35,170,285,665,676],"a":[36,92,518,677,823],"potential":[37],"determining":[38],"factor":[39],"efficacy":[41,634],"toxicity":[43,59,104],"of":[44,77,106,116,168,226,240,292,313,385,398,427,456,495,522,575,593,607,629,637,652,672,708,722,736,927,941,956,975,991,1007,1018,1049,1065,1076,1088,1101,1113],"CAR":[45,78,119,125,180,187,194,247,265,293,314,340,359,378,399,413,428,490,596,608,638,658,673],"cells,":[47],"lower":[49,58],"tumor":[50,88],"being":[52],"associated":[53,214],"improved":[55],"survival":[56,557,560],"(Bishop":[60],"et":[61,67,233],"al.":[62,68,234],"Blood":[63,69],"Advances":[64,70],"2019,":[65],"Dean":[66],"2020).":[71],"However,":[72],"in-vivo":[73],"expansion":[74],"persistence":[76],"are":[81,432],"thought":[82],"to":[83,193,339,358,377,395,454,668],"be":[84,615],"influenced":[85],"by":[86,172],"pre-treatment":[87,630],"play":[91],"role":[93,671],"in":[94,271,281,416,434,440,478,499,620,647,690,1029],"treatment":[95,190,512],"outcomes.":[96],"Here,":[97],"we":[98],"report":[99],"the":[100,114,223,252,290,364,396,417,435,451,462,591,621,627,650,670,691],"characteristics,":[101,191],"outcomes":[102,198,602],"patterns":[105],"DLBCL":[107,143,244,584,684],"no":[110,166,383,482,587],"measurable":[111,386],"diseases":[112],"at":[113,289,504,590,649],"time":[115,291,336,390,453,592,651],"commercial":[117,594],"therapy.":[122,641],"Methods:":[123],"The":[124,303,311,334,388,510,553,571],"Consortium":[128],"includes":[129],"8":[130,410],"US":[131],"academic":[132],"institutions":[133],"that":[134,645],"have":[135],"collected":[136],"data":[137],"on":[138,261,633,704,718,732,923,937,952,971,987,1003,1014,1045,1061,1072,1084,1097,1109],"adult":[139],"R/R":[142,320],"who":[144,367,465,585],"received":[145,297,301,354,368,469,473],"axicabtagene":[146],"ciloleucel":[147],"(axi-cel)":[148],"or":[149,710,724,738,929,943,958,977,993,1009,1020,1051,1067,1078,1090,1103,1115],"tisagenlecleucel":[150],"(tisa-cel)":[151],"between":[152],"April":[153],"2018":[154],"October":[156],"2019.":[157],"This":[158],"multicenter":[159],"retrospective":[160],"study":[161,253],"included":[162,318],"all":[163,371],"evidence":[167,384],"evaluated":[171],"PET/CT":[173,374,393],"scan":[174,375,394],"other":[176],"indicated":[177],"investigations":[178],"before":[179,264],"infusion.":[183,362],"Baseline":[184,423],"demographic":[185],"data,":[186],"therapy,":[197,370],"adverse":[200],"events":[201],"were":[202,218,280],"analyzed":[203],"reported.":[205],"Cytokine":[206],"release":[207],"syndrome":[208,216],"(CRS)":[209],"immune":[211],"effector":[212],"neurotoxicity":[215],"(ICANS)":[217],"reviewed":[219],"re-graded":[221],"using":[222],"American":[224,961],"Society":[225,962],"Transplant":[227],"Cellular":[228,966],"Therapy":[229],"Consensus":[230],"Criteria":[231],"(Lee":[232],"BBMT":[235],"2019).":[236],"Results:":[237],"A":[238],"total":[239],"236":[241],"had":[245,372,586,600],"therapy":[250,356,431],"during":[251],"period":[254],"(151":[255],"axi-cel,":[256],"85":[258],"tisa-cel).":[259,302],"Data":[260,766,777,791],"status":[263],"infusion":[268,295,343,381,401,599,653],"was":[269,306,344,402,438,476,515,561,577],"available":[270],"199":[272,276],"patients.":[273],"Of":[274,363,461],"these":[275],"patients,":[277],"15":[278,496],"(7.5%)":[279],"complete":[282],"(CR),":[284],"per":[286],"investigator":[287],"assessment":[288],"T-cell":[294],"(4":[296,536],"axi-cel":[298,470],"11":[300],"median":[304,335,389,452,519],"age":[305],"61.6":[307],"years":[308],"(range,":[309,347,405,459],"38.1-75.5).":[310],"indications":[312],"treatments":[317,689],"12":[319,494],"de":[321],"novo":[322],"DLBCL,":[323,537],"2":[324,472],"grade":[326],"1":[331,447,457,468,479,538,549,697],"transformed":[332],"DLBCL.":[333],"from":[337,391,545,550,657],"leukapheresis":[338],"48":[345],"days":[346,404],"19-89).":[348],"After":[349],"leukapheresis,":[350],"13":[351,365],"(86.7%)":[353],"bridging":[355,369],"prior":[357,376],"repeated":[373],"showing":[382],"diseases.":[387],"pre-infusion":[392],"day":[397,458,487,505],"14":[403],"6-77)":[406],"7":[408],"having":[412],"inpatient":[418],"outpatient":[420],"settings,":[421],"respectively.":[422],"characteristics":[424],"details":[426],"summarized":[433],"Table.":[436],"CRS":[437],"observed":[439],"3":[441,463],"(20.0%)":[443],"(2":[444],"Grade":[445,448],"1,":[446],"2)":[449],"onset":[455],"0-5).":[460],"developed":[466,484],"CRS,":[467],"tisa-cel.":[474],"Tocilizumab":[475],"provided":[477],"patient":[480],"ICANS.":[485],"At":[486,517],"+100":[488],"after":[489,687],"infusion,":[493],"remained":[498,527],"CR":[500,648,686],"(3":[501,544],"relapsed":[503,535],"+30,":[506],"+64":[507],"+88).":[509],"100-day":[511],"related":[513],"mortality":[514],"0%.":[516],"follow-up":[520],"duration":[521],"20":[523],"months,":[524],"10":[525],"alive":[528],"progression":[530],"free,":[531],"while":[532],"5":[533],"HGBL)":[539],"4":[541],"died":[543],"progressive":[546],"non-relapse":[551],"mortality).":[552],"1-year":[554,572],"event":[555],"free":[556],"overall":[559],"66.0%":[562],"(95%CI":[563,567,579],"45.7-59.4%)":[564],"73.3%":[566],"54.0-99.5%),":[568],"respectively":[569],"(Figure).":[570],"cumulative":[573],"incidence":[574,606],"relapse":[576],"27.3%":[578],"3.4-51.3%).":[580],"Conclusion:":[581],"Patients":[582],"residual":[588],"excellent":[601],"very":[604],"low":[605],"cell-associated":[610],"complications.":[611],"These":[612],"may":[614,654],"managed":[616],"followed":[618],"safely":[619],"ambulatory":[622],"setting.":[623,695],"Our":[624,642],"findings":[625,643],"emphasize":[626],"importance":[628],"tolerability":[636],"suggest":[644],"still":[655],"benefit":[656],"therapies":[661],"could":[663],"serve":[664],"an":[666,705,719,733,924,938,953,972,988,1004,1015,1046,1062,1073,1085,1098,1110],"initiative":[667],"explore":[669],"consolidation":[678],"risk":[683],"achieving":[685],"conventional":[688],"prospective":[692],"clinical":[693],"trial":[694],"Figure":[696,698],"1.":[699],"Disclosures":[700],"Bachanova:":[701],"KaryoPharma:":[702],"Membership":[703,717,731,922,936,951,970,986,1002,1013,1044,1060,1071,1083,1096,1108],"entity's":[706,720,734,925,939,954,973,989,1005,1016,1047,1063,1074,1086,1099,1111],"Board":[707,721,735,926,940,955,974,990,1006,1017,1048,1064,1075,1087,1100,1112],"Directors":[709,723,737,928,942,957,976,992,1008,1019,1050,1066,1077,1089,1102,1114],"advisory":[711,725,739,930,944,959,978,994,1010,1021,1052,1068,1079,1091,1104,1116],"committees;":[712,931,945,960,979,1011,1022,1069,1080,1105,1117],"Incyte:":[713,1001,1136],"Research":[714,727,741,753,757,782,798,802,805,809,826,834,839,843,849,853,857,862,866,870,874,878,882,893,901,907,914,918,999,1034,1039,1054,1093,1119,1122,1126],"Funding;":[715,728,754,758,783,799,803,806,810,835,840,844,850,854,863,867,871,875,879,883,894,902,908,915,1000,1040,1055,1094,1120,1123],"FATE:":[716],"committees,":[726,740,995,1053,1092],"Gamida":[729,855],"Cell:":[730,856],"Funding.":[742,858,919,1127],"Maziarz:":[743],"Artiva":[744],"Therapeutics:":[745,748,808,831,846,891,910,1125,1170],"Consultancy;":[746,749,813,1057],"CRISPR":[747],"Intellia:":[750],"Honoraria;":[751,763,787,889,896,911,968,984,1130,1135,1141,1143,1147,1149,1151,1153,1155,1157,1159,1164],"Omeros:":[752,1158],"Allovir:":[755,836],"Consultancy,":[756,775,786,816,832,837,847,1042,1059,1082,1107],"Bristol-Myers,":[759],"Squibb/Celgene,,":[760],"Intellia,":[761],"Kite:":[762],"Athersys:":[764],"Other:":[765,776,790,818,886,905],"Safety":[768,779,793],"Monitoring":[769,780,794],"Board,":[770],"Patents":[771,947,996],"&":[772,948,997],"Royalties;":[773,949],"Novartis:":[774,797,804,864,985,1041,1131],"board,":[781],"Incyte":[784],"Corporation:":[785],"Vor":[788],"Pharma:":[789,852,885],"Board.":[795],"McGuirk:":[796],"Fresenius":[800],"Biotech:":[801],"Pluristem":[807],"EcoR1":[811],"Capital:":[812],"Kite/":[814],"Gilead:":[815],"Honoraria,":[817,833,838,848,861,865,873,877,881,892,900,904,917,1043,1132,1137,1161,1167,1171],"travel":[819],"accommodations,":[820],"expense,":[821],"Kite":[822],"Gilead":[824],"company,":[825],"Funding,":[827,1035],"Speakers":[828,1036],"Bureau;":[829,1037],"Magenta":[830],"Bellicum":[841],"Pharmaceuticals:":[842],"Juno":[845],"Astelllas":[851],"Nastoupil:":[859],"Epizyme:":[860],"Caribou":[868],"Biosciences:":[869,913],"Janssen:":[872,921,1070],"Gilead/Kite:":[876],"Genentech:":[880],"Denovo":[884],"DSMC;":[887],"Bayer:":[888,1095],"TG":[890],"MorphoSys:":[895,1038,1163],"Bristol":[897],"Myers":[898],"Squibb/Celgene:":[899],"Takeda:":[903,1058,1154],"DSMC,":[906],"ADC":[909],"IGM":[912],"Pfizer:":[916],"Porter:":[920],"National":[932],"Marrow":[933],"Donor":[934],"Program:":[935],"Unity:":[946],"Kite/Gilead:":[950,1033,1160],"Transplantation":[964],"Therapy:":[967],"ASH:":[969],"Wiley":[980],"Sons":[982],"Publishing:":[983],"Royalties,":[998],"DeCart:":[1012],"GenenTech:":[1023],"Current":[1024,1026],"Employment,":[1025],"equity":[1027],"holder":[1028],"publicly-traded":[1030],"company.":[1031],"Riedell:":[1032],"BeiGene:":[1056],"Celgene/BMS:":[1081],"Karyopharm:":[1106,1150],"Calibr:":[1118],"Xencor:":[1121],"Tessa":[1124],"Perales:":[1128],"Cidara:":[1129],"Other;":[1133,1138,1162,1168,1172],"Merck:":[1134],"Bristol-Myers":[1139],"Squibb:":[1140],"Celgene:":[1142],"Sellas":[1144],"Life":[1145],"Sciences:":[1146],"NexImmune:":[1148],"Servier:":[1152],"Equilium:":[1156],"Miltenyi":[1165],"Biotec:":[1166],"Nektar":[1169],"Medigene:":[1173],"Honoraria.":[1174]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2025-10-10T00:00:00"}